Hospital
Capital Health System INC
Capital Health System INC was paid $114.53M by Medicaid between Jan 2018 and Dec 2024, across 330 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoCAPITAL HEALTH SYSTEM INC
TRENTON, NJ 08638
TRENTON, NJ 08638
33aNPI1275583726assigned 05/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$114.53M
24GClaims1,400,639
24DCodes billed330
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#17 of 93
Median peer was paid$30.60M
This provider vs. median3.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 181,837 | $16.45M | |
| 2019 | 184,771 | $15.41M | |
| 2020 | 159,325 | $12.31M | |
| 2021 | 182,909 | $13.82M | |
| 2022 | 200,764 | $14.79M | |
| 2023 | 277,233 | $21.16M | |
| 2024incomplete | 213,800 | $20.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 65,889 | 58,815 | $25.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 70,012 | 60,750 | $24.81M |
| S9480 | Intensive outpatient psychiatric services, per diem | 7.8% | 10,652 | 9,378 | $8.98M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 20,722 | 18,353 | $7.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.3% | 20,181 | 18,484 | $6.05M |
| G0378 | Hospital observation service, per hour | 4.4% | 6,483 | 5,317 | $5.02M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.9% | 15,576 | 14,070 | $3.31M |
| T2034 | Crisis intervention, waiver; per diem | 2.5% | 3,412 | 3,244 | $2.87M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 7,381 | 7,079 | $2.01M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.4% | 25,615 | 16,942 | $1.66M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 13,682 | 12,700 | $1.43M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,608 | 2,503 | $1.23M |
318 more codes
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 3,343 | $1.06M |
| A0429 | Emergency ambulance ride, basic life support | <1% | 6,094 | $853K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 843 | $771K |
| 99241 | <1% | 10,296 | $764K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 72,226 | $750K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,228 | $732K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,357 | $644K |
| 93017 | <1% | 1,301 | $617K | |
| A0434 | Specialty care transport (sct) | <1% | 1,521 | $617K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,173 | $567K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13,628 | $546K |
| 93970 | <1% | 1,646 | $520K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,018 | $516K |
| OP250 | <1% | 30,689 | $483K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 61,736 | $462K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18,245 | $420K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,446 | $411K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 30,011 | $409K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 677 | $378K |
| 73564 | <1% | 3,796 | $368K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,587 | $362K |
| A0425 | Ground mileage, per statute mile | <1% | 26,224 | $345K |
| S9484 | Crisis intervention mental health services, per hour | <1% | 435 | $329K |
| 70486 | <1% | 2,091 | $315K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,557 | $314K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 11,694 | $301K |
| OP272 | <1% | 17,996 | $295K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,172 | $286K |
| 72110 | <1% | 1,683 | $280K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,088 | $278K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,494 | $274K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,920 | $270K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,940 | $267K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,592 | $254K |
| 93971 | <1% | 2,117 | $239K | |
| OP379 | <1% | 2,363 | $229K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,195 | $229K |
| 80053 | Comprehensive metabolic panel | <1% | 49,578 | $223K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 108 | $211K |
| 99242 | <1% | 2,829 | $207K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,359 | $203K |
| 73130 | <1% | 3,148 | $191K | |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 713 | $184K |
| 73030 | <1% | 3,298 | $184K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,068 | $182K |
| 76801 | <1% | 990 | $178K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 671 | $175K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,323 | $172K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,458 | $171K |
| 71250 | <1% | 1,000 | $159K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,793 | $146K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 446 | $142K |
| 73610 | <1% | 3,022 | $141K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,139 | $140K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,294 | $136K |
| 73630 | <1% | 3,317 | $134K | |
| 82948 | <1% | 25,829 | $133K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,511 | $119K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,725 | $106K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,948 | $105K |
| 73502 | <1% | 1,617 | $103K | |
| 72131 | <1% | 689 | $98K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 23,152 | $89K |
| 84484 | <1% | 20,960 | $82K | |
| 76937 | <1% | 995 | $81K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 5,544 | $78K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 755 | $78K |
| OP271 | <1% | 3,457 | $75K | |
| 73110 | <1% | 1,862 | $75K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 85 | $71K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,677 | $70K |
| 86850 | <1% | 6,153 | $69K | |
| 73590 | <1% | 1,162 | $66K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,846 | $64K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 91 | $64K |
| 80051 | <1% | 4,963 | $64K | |
| 90714 | <1% | 2,883 | $61K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 43 | $61K |
| 72100 | <1% | 745 | $58K | |
| 90863 | <1% | 769 | $58K | |
| 81001 | <1% | 31,114 | $57K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 713 | $55K |
| 95811 | <1% | 41 | $53K | |
| 87070 | <1% | 8,539 | $53K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 37 | $52K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 174 | $52K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,776 | $51K |
| 12001 | <1% | 1,412 | $50K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,176 | $49K |
| 86480 | <1% | 979 | $46K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,337 | $45K |
| C1769 | Guide wire | <1% | 1,343 | $44K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,542 | $44K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 2,603 | $43K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,076 | $41K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 209 | $41K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,069 | $39K |
| 86900 | <1% | 6,435 | $39K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,271 | $38K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,241 | $38K |
| 73090 | <1% | 635 | $38K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,693 | $37K |
| 85610 | <1% | 15,608 | $37K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 139 | $37K |
| 73562 | <1% | 1,227 | $36K | |
| 12011 | <1% | 930 | $36K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,951 | $35K |
| 81002 | <1% | 21,911 | $35K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,376 | $35K |
| 73080 | <1% | 890 | $34K | |
| 83880 | <1% | 4,513 | $33K | |
| 87480 | <1% | 3,432 | $33K | |
| 85730 | <1% | 13,165 | $32K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 359 | $32K |
| 83690 | <1% | 16,111 | $31K | |
| 85027 | <1% | 13,401 | $31K | |
| 76536 | <1% | 124 | $30K | |
| 96376 | <1% | 3,496 | $30K | |
| OP270 | <1% | 2,678 | $30K | |
| 36902 | <1% | 38 | $30K | |
| OP258 | <1% | 2,552 | $29K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 268 | $29K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,881 | $29K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,106 | $28K |
| 87077 | <1% | 5,107 | $28K | |
| 84702 | <1% | 3,848 | $28K | |
| 87400 | <1% | 3,570 | $27K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,293 | $27K |
| 90715 | <1% | 3,703 | $27K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,933 | $27K |
| 87660 | <1% | 3,428 | $26K | |
| 87510 | <1% | 3,430 | $26K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 25 | $26K |
| 72050 | <1% | 148 | $25K | |
| 87040 | <1% | 3,469 | $25K | |
| 73140 | <1% | 1,214 | $24K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,356 | $23K |
| 97161 | <1% | 1,236 | $23K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,301 | $23K |
| 83605 | <1% | 5,444 | $23K | |
| 10060 | <1% | 438 | $22K | |
| J3490 | Unclassified drugs | <1% | 2,756 | $21K |
| 86901 | <1% | 6,440 | $21K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 789 | $20K |
| 81401 | <1% | 277 | $20K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 332 | $20K |
| 83735 | <1% | 11,152 | $20K | |
| 74018 | <1% | 609 | $20K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,609 | $18K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,047 | $17K |
| 94729 | <1% | 250 | $17K | |
| 90686 | <1% | 1,517 | $17K | |
| 97010 | <1% | 6,701 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,224 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,308 | $16K |
| 86803 | <1% | 1,016 | $16K | |
| 82728 | <1% | 1,605 | $15K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,462 | $15K |
| 87186 | <1% | 3,231 | $14K | |
| 70498 | <1% | 105 | $14K | |
| 70496 | <1% | 72 | $14K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 209 | $13K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 814 | $13K |
| 97165 | <1% | 961 | $13K | |
| 12002 | <1% | 239 | $13K | |
| 80061 | Lipid panel | <1% | 1,786 | $12K |
| 76770 | <1% | 56 | $12K | |
| 96367 | <1% | 785 | $12K | |
| 94375 | <1% | 256 | $12K | |
| 85007 | <1% | 8,939 | $12K | |
| 85379 | <1% | 2,905 | $12K | |
| 29125 | <1% | 634 | $11K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,824 | $11K |
| 94760 | <1% | 1,968 | $11K | |
| 97162 | <1% | 626 | $10K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,696 | $10K |
| 72128 | <1% | 115 | $10K | |
| 83021 | <1% | 484 | $10K | |
| 90678 | <1% | 56 | $10K | |
| 29540 | <1% | 782 | $10K | |
| 80076 | <1% | 2,924 | $9K | |
| 94726 | <1% | 178 | $9K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,250 | $9K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 275 | $9K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,885 | $9K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 80 | $9K |
| 86787 | <1% | 685 | $8K | |
| 94200 | <1% | 246 | $8K | |
| 94664 | <1% | 244 | $8K | |
| 82805 | <1% | 1,584 | $8K | |
| 82550 | <1% | 2,596 | $8K | |
| 86140 | <1% | 1,856 | $7K | |
| 81003 | <1% | 2,790 | $7K | |
| 80164 | <1% | 983 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,216 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,243 | $6K |
| 81511 | <1% | 75 | $6K | |
| 73552 | <1% | 194 | $6K | |
| 70491 | <1% | 26 | $6K | |
| 29530 | <1% | 379 | $6K | |
| 87340 | <1% | 1,192 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 387 | $5K |
| 90675 | <1% | 29 | $5K | |
| 97116 | <1% | 1,403 | $5K | |
| 72040 | <1% | 97 | $5K | |
| 86702 | <1% | 333 | $5K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 289 | $5K |
| 86701 | <1% | 333 | $4K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 509 | $4K |
| 73060 | <1% | 104 | $4K | |
| 82565 | <1% | 5,007 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 694 | $4K |
| 76870 | <1% | 41 | $4K | |
| 84439 | <1% | 911 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,759 | $4K |
| 81025 | <1% | 1,006 | $3K | |
| 84520 | <1% | 4,957 | $3K | |
| 87807 | <1% | 775 | $3K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 730 | $3K |
| 82248 | <1% | 825 | $3K | |
| 88142 | <1% | 159 | $3K | |
| 74021 | <1% | 319 | $3K | |
| 87081 | <1% | 279 | $3K | |
| 88342 | <1% | 164 | $2K | |
| 84100 | <1% | 2,731 | $2K | |
| 86762 | <1% | 664 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,571 | $2K |
| 71101 | <1% | 85 | $2K | |
| 85049 | <1% | 413 | $2K | |
| 85651 | <1% | 1,054 | $2K | |
| 97164 | <1% | 46 | $2K | |
| 85014 | <1% | 1,589 | $2K | |
| 90658 | <1% | 118 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 169 | $2K |
| 85018 | <1% | 1,396 | $2K | |
| 84145 | <1% | 455 | $2K | |
| 96368 | <1% | 80 | $2K | |
| 87205 | <1% | 525 | $2K | |
| 86592 | <1% | 1,816 | $2K | |
| 82247 | <1% | 652 | $1K | |
| 29130 | <1% | 77 | $1K | |
| 94762 | <1% | 26 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 370 | $1K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 143 | $1K |
| 76775 | <1% | 12 | $1K | |
| 82950 | <1% | 362 | $1K | |
| 74022 | <1% | 194 | $1K | |
| 71271 | <1% | 16 | $1K | |
| OP279 | <1% | 152 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 660 | $1K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 43 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 42 | $1K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 315 | $1K |
| 82330 | <1% | 55 | $1K | |
| 97166 | <1% | 108 | $989.90 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $905.99 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 618 | $894.31 |
| 84703 | <1% | 614 | $892.54 | |
| 94761 | <1% | 197 | $772.70 | |
| OP229 | <1% | 15 | $769.95 | |
| 51701 | <1% | 40 | $699.25 | |
| 29515 | <1% | 82 | $637.83 | |
| 85041 | <1% | 427 | $573.35 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 14 | $547.04 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 14 | $547.04 |
| 84132 | <1% | 668 | $521.38 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 26 | $504.46 |
| 84460 | <1% | 225 | $501.26 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $495.25 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 475 | $485.28 |
| 84450 | <1% | 189 | $482.46 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $480.26 |
| 73620 | <1% | 18 | $439.60 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 40 | $430.37 |
| 99201 | <1% | 12 | $414.31 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 13 | $402.62 |
| 73660 | <1% | 51 | $395.99 | |
| 88304 | <1% | 13 | $363.86 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 60 | $363.02 |
| 82570 | <1% | 174 | $295.28 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 151 | $288.06 |
| 83615 | <1% | 140 | $263.98 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 27 | $246.95 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 34 | $207.56 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 409 | $193.48 |
| 84550 | <1% | 96 | $189.58 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 280 | $189.27 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 112 | $189.15 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 544 | $172.45 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 461 | $168.82 |
| 74019 | <1% | 26 | $152.81 | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 19 | $147.74 |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 123 | $139.59 |
| 82607 | <1% | 41 | $134.32 | |
| 83540 | <1% | 131 | $133.14 | |
| 72170 | <1% | 12 | $129.18 | |
| 83550 | <1% | 83 | $124.84 | |
| 82043 | <1% | 12 | $124.06 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 29 | $116.66 |
| 82150 | <1% | 16 | $116.43 | |
| 86706 | <1% | 12 | $113.97 | |
| 82105 | <1% | 12 | $98.24 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 49 | $89.72 |
| 90656 | <1% | 19 | $81.19 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 29 | $78.13 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 20 | $76.64 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 16 | $72.13 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 33 | $57.88 |
| 85384 | <1% | 36 | $51.92 | |
| 84156 | <1% | 13 | $21.78 | |
| 84295 | <1% | 91 | $21.61 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 16 | $15.84 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 47 | $8.85 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 17 | $6.43 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 12 | $1.63 |
| J7999 | Compounded drug, not otherwise classified | 0% | 27 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 648 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVISCONTI, DEBORAH (DIRECTOR OF PATIENT ACCOUNTS)
| Provider | Location | Paid |
|---|---|---|
| Capital Health System, INC. | Pennington, NJ | $132.16M |
| Capital Health System INC | Trenton, NJ | $6.14M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.